Chief R&D Officer of Nektar Therapeutics (NASDAQ:NKTR), Zalevsky Jonathan, sells 16,380 shares worth $268,632
According to Nektar Therapeutics's most recent Statement Of Changes In Beneficial Ownership - Form 4 filing with the SEC dated Nov 25 06:09 PM, company Chief R&D Officer, Zalevsky Jonathan disclosed selling 16,380 shares at a cost of $16.40. At the time of this transaction (Nov 23), this trade was worth $268,632 in total. As of Nov 23, Zalevsky Jonathan now owns 250,317 shares in total worth about $4,125,224.16.
For the last few recent trades made by Nektar Therapeutics (NASDAQ:NKTR) Chief R&D Officer, Zalevsky Jonathan, we have the following information:
- SEC Form 4 filing: Nov 16: Sold 29,618 shares at the rate of $16.93 per share. Total worth of this trade was $501,433. Total number of shares owned as of Nov 16 were 266,697
- SEC Form 4 filing: Aug 17: Sold 26,200 shares at the rate of $19.67 per share. Total worth of this trade was $515,354. Total number of shares owned as of Aug 17 were 296,315
- SEC Form 4 filing: May 18: Sold 4,558 shares at the rate of $22.51 per share. Total worth of this trade was $102,601. Total number of shares owned as of May 18 were 322,515
Posted by
George Daniels
on Thursday November 26 2020, 1:34 PM EDT.
All trademarks acknowledged.
Filed under Business, Stocks.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
